



Amarin to Present at the Cowen and Company Healthcare Conference

DUBLIN and MYSTIC, Conn., March 3 /PRNewswire-FirstCall/ --Amarin Corporation plc (Nasdaq:[AMRN](#) - [News](#)) today announced that John F. Thero, Chief Financial Officer, is scheduled to present at Cowen and Company's 30th Annual Healthcare Conference on Wednesday, March 10, 2010 at 8:45 am Eastern Time. This conference will be held at the Boston Marriott Copley Place.

A live audio webcast of the presentation will be available at the following URL:

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=AMRN&item_id=2757838

A replay of the presentation will be available at the same URL for 30 days.

About Amarin

Amarin is a clinical-stage biopharmaceutical company with expertise in lipid science focused the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), has commenced enrollment of patients in two pivotal Phase 3 clinical trials for the treatment of patients with very high triglyceride levels and for the treatment of patients with high triglycerides with mixed dyslipidemia. Both of these Phase 3 trials were designed under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit <http://www.amarincorp.com/>.

Contacts:

Investor Contact Information:

John F. Thero

Chief Financial Officer

In US: +1 (860) 572 4979

investor.relations@amarincorp.com

Gitanjali Ogawa

The Trout Group

In US +1 (646) 378-2949

gogawa@troutgroup.com